These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cyclophosphamide, vincristine, lomustine, cisplatin, and doxorubicin in the treatment of non-small cell lung cancer.
    Author: Pearlman NW, Meyers TJ, Siebert PE, Wallner SF, Carson SD, Campbell DN, Johnson FB, Kennaugh R, Rempel P.
    Journal: Cancer Treat Rep; 1983 Apr; 67(4):375-6. PubMed ID: 6303587.
    Abstract:
    Fifty-four patients (47 of whom were evaluable) with non-small cell lung cancer were treated with a five-drug regimen consisting of cyclophosphamide, vincristine, lomustine, cisplatin, and doxorubicin. Six complete and 16 partial responses were achieved, for an overall response rate of 47% (22 of 47 patients). Response by cell type was as follows: epidermoid carcinoma, 41% (seven of 17 patients); adenocarcinoma, 42% (eight of 19); and large cell carcinoma, 64% (seven of 11). Response in patients with limited disease was 48% (11 of 23 patients) and in patients with extensive disease, 46% (11 of 24). Previously untreated patients had response rates of 53%, versus 22% in those with prior therapy.
    [Abstract] [Full Text] [Related] [New Search]